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Open access unObjective: High-risk prostate cancer patients are at risk for subclinical disease and micro-metastasis at
the time of treatment. Nowadays, tight margins reduce dose to periprostatic areas compared to earlier
techniques. We investigated whether rectangular ﬁelds were associated with fewer failures compared
to conformal ﬁelds (with lower extraprostatic dose).
Methods: We selected 164 high-risk patients from the trial population of 266 T1-T4N0M0 patients, ran-
domized between rectangular (n = 79) and conformal ﬁelds (n = 85). Prescribed dose was 66 Gy to the
prostate and seminal vesicles plus 15 mm margin. We compared clinical failure rates (in- and excluding
local failures), between both arms. Dose differences around the prostate were calculated based on an
inter-patient mapping method.
Results: Median follow-up was 34 months. There were 9 clinical failures in the rectangular arm versus 24
in the conformal arm (p = 0.012). Number of failures outside the prostate was 7 and 19, respectively
(p = 0.025). We observed average dose differences of 5–35 Gy between the arms in the regions around
the prostate.
Conclusions: We found a signiﬁcantly lower risk of early tumor progression for patients treated with rect-
angular ﬁelds. Treatment failure can probably in part be prevented by irradiation of areas suspected of
subclinical disease in high-risk prostate cancer.
 2013 Elsevier Ireland Ltd. Radiotherapy and Oncology 107 (2013) 134–139 Open access under CC BY-NC-NDPatients treated with radiotherapy for localized prostate cancer
have different risk proﬁles with regard to recurrence of the disease
and prostate cancer-related death. Well established predictive fac-
tors are: pretreatment Prostate-Speciﬁc Antigen (PSA) level, T
stage, and Gleason score/differentiation grade. These factors are
broadly recognized and used to deﬁne low-, intermediate- and
high-risk prostate cancer. The deﬁnition of Chism et al. [1] identi-
ﬁes low risk as PSA 6 10, T1B-T2a, and Gleason < 7, high-risk as
PSA > 20 ug/L, and/or T3, and/or Gleason 8–10, and intermediate
risk as all other patients.
High-risk patients show a much higher hazard rate for clinical
failures during the ﬁrst years after radiotherapy compared to
low- and intermediate risk. This can be contributed to extracapsu-
lar cancer growth into surrounding tissues (e.g. invasion of rectum
or bladder neck, perineural invasion), and micro-metastasis to
lymph node areas already present at the time of radiotherapy [2–adiation Oncology, The Neth-
Hospital, Plesmanlaan 121,
msbergen).
der CC BY-NC-ND license.6]. Clinical failures after a longer period of time (e.g. 10 years)
can be contributed to local failure of the treatment [2]. Risk estima-
tions of subclinical disease outside the prostate vary from a few
percent for low-risk patients to more than 30% for high-risk,
depending on the risk proﬁle [6,7].
Elective nodal irradiation in patients with unfavorable prostate
cancer is a controversial topic; the presence of micro-metastasis in
part of these patients suggests favorable outcomes for elective irra-
diation, but results from two randomized trials are inconclusive
[8,9]. Therefore elective nodal irradiation has remained a point of
discussion since the introduction of conformal therapy about
20 years ago [10].
In a previous study we found a dose–effect relationship for acci-
dental dose delivered outside the prostate and freedom from failure
[11]. This concerned a subgroup of high-risk patients from a ran-
domized trial in which either 68 Gy or 78 Gy was described to
the prostate and seminal vesicles with conformal techniques and
a 1 cm margin. To validate the results of this explorative analysis,
we investigated failure rates of high-risk prostate cancer patients
in an independent data set. This concerned data of a previous ran-
domized clinical trial [12] in which the original goal was to look
W.D. Heemsbergen et al. / Radiotherapy and Oncology 107 (2013) 134–139 135into toxicity levels of conformal ﬁelds compared to rectangular
ﬁelds. All patients in this trial were treated with modern three-
dimensional (3D) treatment techniques and their setup was mon-
itored and corrected when necessary during treatment. In this tox-
icity trial patient had been randomized between rectangular ﬁelds
to treat the prostate and seminal vesicles, and conformal ﬁelds
(with lower unintended dose to regional areas). Our hypothesis
was that rectangular ﬁelds may be associated with a lower risk
of clinical failure.
Material and methods
Study Population
We reviewed data from a randomized clinical trial performed at
the Daniel den Hoed Clinic/Erasmus Medical Center in Rotterdam
(The Netherlands). Patient recruitment took place in the period
1994–1996. A total of 266 patients entered this toxicity trial in
which adverse toxicity event rates were compared between treat-
ments with conformal ﬁelds versus the conventional (at that time)
rectangular ﬁelds. More details of this study population are de-
scribed elsewhere [12]. From this patient group, we selected 164
high-risk patients, using criteria described by Chism et al. [1]:
PSA > 20 lg/L, or poor differentiation, or T3. Since no Gleason score
was available for these patients diagnosed in 1994–1996, we used
the differentiation grade to select high-risk patients. Characteris-
tics of the selected high-risk patients are summarized in Table 1.
Trial patients with T1B/C tumors were treated for the prostate only
and therefore none of them were selected for the current analysis:
this excluded 2 high-risk patients with a T1B tumor and poor
differentiation.Treatment
Patients were randomized to either rectangular or conformal
radiation ﬁelds, stratifying for gross tumor volume. The prescribed
dose was 66 Gy in 33 fractions. Patients were instructed to have a
full bladder and empty rectum for the planning CT scan. The clin-
ical target volume was the prostate and seminal vesicles plus a 3D
expansion of 15 mm. A three-ﬁeld technique was used with two
lateral (oblique) ﬁelds and one anterior treatment ﬁeld whichTable 1
Patient and treatment data of selected high-risk patients (n = 164).
Characteristics Rectangular ﬁelds
(n = 79)
Conformal ﬁelds
(n = 85)
Mean age in years (1 SD) 70 (6.5) 70 (6.4)
Tumor stage:
T2A 2 1
T2B 9 7
T2C 22 19
T3A 15 27
T3B 29 22
PSA (lg/L)
<10 13 15
10–20 19 24
>20 46 45
Unknown 1 1
Differentiation grade
Good 17 21
Moderate 44 34
Poor 16 25
Unknown 2 5
Neo-adjuvant HTa:
Yes 15 12
No 64 73
a HT, hormonal treatment.was planned with a 3D planning system (CADPLAN). In the confor-
mal arm, a multi leaf collimator was used to shape the treatment
ﬁelds. Patient set-up was checked at regular intervals using an
electronic portal imaging device. During treatment an Electronic
Portal Imaging Device was used to check the patient setup. With
‘‘a set-up correction protocol’’ [13] the average systematic posi-
tioning accuracy of the bony anatomy could be limited to
1.5 mm (1 SD) with a average random error of 2.5 mm (1 SD).
Endpoint
No data on follow-up PSA measures or biochemical failure were
available for this patient group. Therefore only clinical failure was
the study endpoint. Failure could be local, regional, and/or distant
metastasis. Procedures to investigate clinical failures were similar
in both arms, and were performed according the clinical guide-
lines: physical exam and blood tests were performed at each fol-
low-up, and if there was an indication for possible tumor
progression, additional imaging (like bone scan, CT scan) was per-
formed as decided by the treating physician. The clinical failures in
this study were all identiﬁed within 3.6 years after treatment.
Longer follow-up was not available from this randomized trial
since it was designed as a toxicity study.Dose distributions
We calculated dose maps for each patient, and constructed a
dose difference map, by using a mapping procedure which is de-
scribed by Witte et al. [11]. The dose mapping is based on the pros-
tate contour delineated on the planning CT scan. From one patient
to another, two points correspond if their distances to the prostate
are equal, and their directions with respect to the center of mass of
the prostate are the same. We also evaluated the dose in speciﬁc
points on the dose map for each individual patient: 3.5 cm and
5 cm from the prostate edge, located in the obturator region. An
example of the location of such a point is illustrated in Fig. 1 for
two arbitrary patients.Statistical analysis
We calculated time-to-event curves from the start of RT, using
Kaplan Meier estimates. Log-Rank statistic was applied to test dif-
ferences between groups. A Cox regression model was used to con-
struct a multivariate model. IBM SPSS for Windows software
was used for the analyses (release 20.0, IBM Corp.).
Results
Tumor progression & survival
Median follow-up was 34 months for patients alive (range 11–
48). The number of patients with tumor progression was 9 in the
rectangular arm and 24 in the conformal arm (total of 33). The ﬁrst
location of established tumor progression was ‘‘local’’ in 7 cases,
‘‘regional’’ in 2 cases, and ‘‘distant metastasis’’ in 24 cases (Table 2).
Kaplan Meier estimates showed a signiﬁcantly lower risk of the to-
tal number of clinical failures for rectangular ﬁelds (p = 0.012,
Fig. 2). When we count only ﬁrst failures outside the prostate
(excluding ﬁrst events of local failure), the number of events was
7 and 19, respectively (Log-Rank, p = 0.025). Within the limited fol-
low-up of the study population 24 patients had died (12 in both
arms); 6 of them died from prostate cancer (3 in both arms).Dose differences
Using the dose mapping procedure, we found average dose dif-
ferences in the range of 5–35 Gy between the arms in the regions
Fig. 1. CT view of two sample patients. The star indicates the position of the two arbitrary chosen points, 3.5 cm (left) and 5 cm (right) from the prostate edge.
Table 2
First failure type.
First failure type Total
NEDa Dead NEDa Local Regional Metastasis
Treatment ﬁeld Rectangular 68 2 2 2 5 79
Conformal 56 5 5 0 19 85
Total 124 7 7 2 24 164
a NED, no evidence of disease.
Fig. 2. Freedom from clinical failure for high-risk prostate cancer patients:
rectangular arm versus conformal arm.
136 Fewer failures with rectangular ﬁeldsaround the prostate, which is shown in Figs. 3 and 4. In Fig. 3 we
plotted isodose difference lines (5, 15, 25 Gy) on a sagittal and
coronal CT view of a sample patient. In Fig. 4 the dose distributions
in the two chosen points in the region around the prostate are
illustrated for each arm separately. The effect of wider margins
in the rectangular group is visualized in these histograms. At a dis-
tance of 3.5 cm in the obturator region, the median dose was
64.4 Gy in the rectangular arm and 60.2 Gy in the conformal arm.
At 5 cm distance, differences are larger: the median dose was
59.4 Gy and 42.0 Gy, respectively (both p < 0.001). There are a
few patients in the rectangular arm with a relatively low dose5 cm from the prostate edge: in these cases the delineated seminal
vesicles were almost at the same height as the prostate (or lower),
in the cranial direction.
Multivariate analysis
We checked the prognostic value of treatment arm in a multi-
variate Cox regression model with t stage, pretreatment PSA and
differentiation grade. Only treatment arm (p = 0.030) and differen-
tiation grade (p < 0.001) were signiﬁcant predictors for clinical fail-
ure in the MV model.
Discussion
We found signiﬁcantly fewer clinical failures for high-risk pros-
tate cancer patients treated with rectangular ﬁelds, compared to
conformal ﬁelds. Also the number of failures outside the prostate
(excluding local progression) was signiﬁcantly lower in the rectan-
gular arm. Furthermore, we found relevant and signiﬁcant dose dif-
ferences when we compare the dose distributions between the
arms: on average higher dose was delivered outside the prostate
in the rectangular arm (e.g. in periprostatic tissues, obturatorial
and presacral regions). These regions are in close correspondence
with the regions indicated in the previous study [11].
The irradiated volumes in this trial are small compared to elec-
tive pelvic irradiation ﬁelds, and the delivered dose to the lymph
node areas in this study is for many cases lower than the optimal
dose of at least 46 Gy. The observed gain in tumor control for rect-
angular ﬁelds is probably twofold: ﬁrstly, unintended irradiation of
lymph node areas is advantageous for a number of patients, and
secondly, areas adjacent to the prostate suspect for subclinical dis-
ease received a higher dose as well, preventing early failure. For
high-risk patients, the numbers of reported cases with tumor cells
outside the prostate are high: positive lymph nodes in 64% of Glea-
son 8–10 (pathological score), 39% of PSA > 20 lg/L, and 37% of pT3
cases [6], but also perineural invasion in 49% [3], bladder neck
involvement in 15% of T3 patients [5], extra-capsular extensions
Fig. 3. Dose differences between rectangular and conformal arm (iso dose lines). Coronal (left) plus sagittal (right) CT view of a sample patient. The dotted line indicates the
position of the other CT view.
Fig. 4. Histograms of dose in the obturator region within the rectangular and conformal group, 3.5 cm and 5 cm from the prostate edge.
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higher dose to all of the involved areas and will lower the tumor
burden of high-risk cases with extra-prostatic disease and there-
fore prevent early clinical failures in a number of cases.
When we compare our study population of high-risk patients to
the patients treated in the pelvic irradiation trial of Pommier et al.,
[8], we notice that their trial also treated low- to intermediate risk
patients (50% had an estimated nodal involvement <15%). In the
RTOG 94–13 trial of Lawton et al. [9], all patients had an estimated
nodal involvement of >15% similar to our population, however,
their patients were randomized as well to receive neoadjuvant hor-
monal treatment (NHT) or adjuvant hormonal treatment (AHT). In
our study only 16% received NHT or AHT, therefore it is difﬁcult to
compare results. Their results were not conclusive about the effect
of pelvic RT: they reported a trend of a favorable outcome in pa-
tients treated with pelvic ﬁelds and NHT compared to the other
arms, although the main comparison yielded no signiﬁcant differ-
ences between pelvic ﬁelds and prostate only.In the current trial, patients were treated with modern 3D irra-
diation techniques, and the treatment included a patient setup cor-
rection protocol, limiting the systematic positioning accuracy of
the bony anatomy to 1.5 mm (1 SD) with a random error of
2.5 mm (1 SD) [12]. Van Herk et al. [14] showed that with this
accuracy 15 mm is a very safe margin. Furthermore, they showed
that the total sum of systematic errors (1 SD) has to be larger than
5 mm before the Tumor Control Probability will drop with P1%
due to geometric miss of the prostate, and that a 10 mm margin
is sufﬁcient to cover for the measured uncertainties in prostate
cancer when an ofﬂine protocol is used.
Nowadays, prostate markers, cone beam CT, and online setup
strategies make it possible to use tighter dose distributions, reduc-
ing the unintended dose to areas around the prostate. Margins of
about 5–7 mm are applied, and steep dose-gradients are obtained
with advanced intensity modulated planning techniques. A num-
ber of high-risk prostate cancer patients are, however, likely to de-
velop progression of disease outside the prostate regardless the
138 Fewer failures with rectangular ﬁeldslocal control status. Teh et al. suggested in their study on extra-
capsular extensions of prostate cancer [4] that planning target vol-
umes should include subclinical disease as well. Several studies re-
port a loss in tumor control in the case of tight margins and
distended rectums at planning [15,16], and in one of these studies
this loss in tumor control was also observed when prostate mark-
ers were used for patient positioning, suggesting geographical miss
of (extra-capsular) subclinical disease [16].
Tighter margins and steeper dose-gradients lower the compli-
cation probabilities and make it feasible to increase the prescribed
dose to the prostate. While this can be expected to increase local
control, a decrease in regional control could be the unintended
side-effect. One can therefore argue whether higher dose inside
the prostate is the best solution for high-risk patients. Our results
suggest that high-risk patients may beneﬁt from limited elective
irradiation at nodal and/or local extraprostatic areas, to cover for
tumor extensions, rectum or bladder involvement and/or (micro)
metastasis to lymph nodes. New techniques with intensity modu-
lated radiotherapy have become available for a safe delivery of
dose to lymph node areas without unacceptable dose levels to sur-
rounding organs at risk [10,17]. It remains however difﬁcult with
the current diagnostic techniques to select the patients that will
beneﬁt most from elective irradiation, and to outline the individual
relevant elective areas. Since a higher rate of toxicity is only
acceptable if the patient is likely to beneﬁt from it by means of pro-
longed survival, this will probably remain a controversial topic in
the near future until improved methods and imaging procedures
are available for a more reliable diagnosis concerning identiﬁcation
of micro-metastases and tumor growth in periprostatic tissues.
We evaluated patients treated in another era. Nowadays, hor-
monal treatment (HT) has become a standard adjuvant treatment
in high-risk prostate cancer. Nevertheless, whether dose to peri-
prostatic tissues and nodal areas is needed in (a part of) this
high-risk patient population still remains a topical subject. Nowa-
days, we do not observe many early failures after radiotherapy in
high-risk patients because hormonal treatment has become a stan-
dard adjuvant treatment. However, subclinical disease outside the
prostate at the time of treatment will eventually cause tumor pro-
gression once hormonal treatment is completed or when the tumor
cells become less sensitive to it [10]. In a previous paper of our
group [11] where we reported on a dose–effect relationship for
dose outside the prostate in 352 patients treated between 1997
and 2003, 34% of the patients were treated with radiotherapy plus
hormonal therapy. The described relationship was seen both in
radiotherapy alone patients and in the ‘‘radiotherapy plus hor-
monal therapy’’ patients.
The dose distribution outside the prostate in this trial looks dif-
ferent from dose distributions in current clinical practice, since the
prescribed dose of 66 Gy is low and the applied margins are too
generous. However, this data set remains very interesting to eval-
uate whether there exists a relationship between rectangular ﬁelds
(with higher dose delivered outside the prostate) and early clinical
failure. The question where this subclinical disease is located, and
which dose distributions outside the prostate are most optimal for
high-risk cases cannot be answered from these data.
The results of the current study should be interpreted carefully
since there are some limitations. This trial was not powered and
designed for the current study objective. Data on follow-up PSA
measurements were not available, and long-term follow-up on
survival and prostate cancer related death was not available either.
Therefore we were not able to investigate whether this had an im-
pact on prostate cancer speciﬁc mortality and overall survival. At
the time of study, imaging techniques to identify local and regional
failures were less conclusive compared to the techniques nowa-
days. Therefore we were not able to establish the difference in re-
gional failures rates between the two arms. We ﬁnd that the dataset was however suitable to test our hypothesis from the previous
study whether incidental dose outside the prostate is indeed re-
lated to tumor progression in high-risk patients. Since it concerned
data from a prospective randomized trial, the quality of the data
was warranted and therefore interesting to use as an independent
data set to test our hypothesis.Conclusions
In a prior investigation we concluded that incidental dose out-
side the prostate was associated with failure in high-risk prostate
cancer patients treated for the prostate and seminal vesicles only
[11]. The current study conﬁrms the ﬁndings of that study in an
independent patient group with quite different treatment charac-
teristics. The progression of subclinical disease in regions around
the prostate can possibly be prevented by limited elective irradia-
tion of lymph node areas and inclusion of subclinical disease in
periprostatic tissues. In order to establish which patients would
beneﬁt most from such treatment, and which areas should be in-
cluded, further investigations are needed.Conﬂicts of interest
None.
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